SANUWAVE Health, Inc. is an emerging leader in the development and commercialization of a high- energy, focused, shock wave technology that is used in devices for the repair and regeneration of bones, muscles, tendons and skin, and for the separation of solids and fluid in non-medical systems.
Within healthcare, SANUWAVE’s proprietary, patented Pulsed Acoustic Cellular Expression (PACE) technology emits high-energy, acoustic shock waves that restore the body’s normal healing processes. This activates biologic signaling which leads to tissue repair and regeneration and blood vessel growth – revascularization and microcirculatory enhancement.
SANUWAVE has three devices that employ the PACE technology. The lead device for the global wound care market, dermaPACE®, is approved for use outside the United States (CE Marked) for advanced wound care indications and is currently being studied in a U.S-based supplemental pivotal clinical trial for diabetic foot ulcers. The orthoPACE® device is CE Marked for orthopedic and musculoskeletal indications. OssaTron®, the Company’s legacy device, is approved by the FDA for multiple orthopedic conditions which have failed to respond to conservative treatment.
In addition, SANUWAVE has patented the use of its shock wave technology in non-medical fields, including energy (improved/enhanced oil recovery), water (purification), food (bacterial reduction), and industrial effluent (particulate separation), and is working toward licensing/partnership relationships.
Headquartered in Alpharetta, Georgia, SANUWAVE designs, manufactures, markets, and services its industry leading products for worldwide distribution.